Next-generation carrier screening: are we ready? by Thomas W Prior
Prior Genome Medicine 2014, 6:62
http://genomemedicine.com/content/6/8/62COMMENTNext-generation carrier screening: are we ready?
Thomas W PriorEditorial summary
Next-generation sequencing (NGS) methodology allows
for a major expansion in current carrier screening tests.
NGS testing has been shown to be analytically accurate
and cost-effective, but major challenges include
educational and counseling issues.pilot studies should be performed. The results of pilotIn the molecular diagnostic laboratory, carrier testing is
often performed on individuals with a known family his-
tory of disease. This type of directed carrier testing is
relatively straightforward because there is a known his-
tory of the disorder and because the causative mutation
has often been identified in the proband. The goal of
population-based carrier screening is to identify couples
who are at risk of having a child with the disorder with-
out the need for a family history, thus allowing carriers
to make informed reproductive choices. It is generally
accepted that the following five criteria should be met in
order for a screening program to be successful: first, the
disorder is clinically severe; second, there is a high fre-
quency of carriers in the screened population; third, a
reliable test with a high specificity and sensitivity that is
relatively inexpensive is available; fourth, prenatal diagno-
sis is available; fifth, there is access to genetic counseling.
Regardless of the reliability of the technology used for
detecting carriers, an educational component including
formal genetic counseling services is absolutely essential.
It is important that all individuals undergoing testing
understand that a carrier is a healthy individual who is
not at risk of developing the disease, but who has a risk of
passing the gene mutation on to his/her offspring. Coun-
seling must also include a description of the disorder,
therapeutic strategies, and prognosis. Educational ma-
terial about the disorder should also be made available
to all couples, preferably in the pre-conception period,
so that they can understand the limitations of the test-
ing. All identified carriers should be referred for follow-
up genetic counseling that includes a discussion of riskCorrespondence: Thomas.Prior@osumc.edu
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implantation diagnosis should be offered. As is true for
all carrier screening programs, the testing is voluntary.
Informed consent and the usual caveats, including issues
relating to confidentiality, paternity, discrimination, self-
esteem and cost, must be addressed. Last, before wide-
spread adoption of a carrier-screening program, prospective
studies often help researchers to project outcomes and
to complete a realistic national picture of what might be
expected from large-scale programs.Brief history
Carrier screening for those without a family history was
initially confined to screening for genetic disorders that
were known to occur with high frequencies in specific
ethnicities. The first genetic disorder for which systematic
carrier screening was undertaken was Tay-Sachs disease,
which has increased prevalence in Eastern European Jewish
(Ashkenazi) individuals. Tay-Sachs disease serves as a
model disease for carrier screening as it meets all the
criteria described earlier. It is an autosomal recessive
neurodegenerative disorder that presents in the first
year of life and is fatal in early childhood. There is no
effective treatment available.
The disease is caused by a mutation in the gene that
encodes β-hexosaminase A (HexA), which results in the
accumulation of a glycolipid, the ganglioside Gm2, within
the lysosome. This leads to blindness, loss of neurologic
function and death between the ages of 2 and 4 years. In
the Ashkenazi population, Tay-Sachs disease has a very
high incidence of about 1:3,000 and a carrier frequency of
1:30. Screening is based on a biochemical assay that mea-
sures the activity of Hex A. DNA testing for the three
most common mutations that are associated with the
disease has been suggested as an alternative to biochem-
ical testing, as 93 to 99% of carriers in the Ashkenazi
population will be positive for one of the mutations.
The screening has been extremely successful and has
led to a reduction of approximately 90% in disease inci-
dence [1]. Today, owing to the success of the Tay-Sachs
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disorders [2].
Cystic fibrosis (CF) is an autosomally recessive inherited
disorder that is characterized by the classic triad of ob-
structive pulmonary disease, pancreatic insufficiency and
elevated chloride levels in sweat. The disease is caused by
mutations in the gene that encodes the cystic fibrosis
transmembrane regulator (CFTR). More than 1,900 muta-
tions have been identified in the gene. CF has a carrier
frequency of about 1 in 25 in individuals of northern
European descent, but occurs at a lower frequency in
other ethnic groups. Since 2001, in response to data
from several funded CF carrier screening pilot projects,
the American College of Obstetricians and Gynecolo-
gists (ACOG) and the American College of Medical
Genetics (ACMG) have recommended offering CF car-
rier screening to all pregnant women [3].
Both the ACOG and the ACMG recommend use of a
23-mutation panel, which tests for all CF-associated muta-
tions with an allele frequency of at least 0.1% in the gen-
eral US population. Although carrier testing for Tay-Sachs
disease among the Ashkenazi population has a test sensi-
tivity of nearly 100%, CF screening using the 23-mutation
CFTR panel has a lower sensitivity of approximately 80%
in Northern Europeans. Several laboratories offer testing
for more mutations (expanded panels) than are screened
for in the testing recommended by ACMG or ACOG. The
benefit of expanded panels is uncertain. A panel that can
identify the presence or absence of additional mutations
only provides a marginal increase in sensitivity in identify-
ing CF carriers, and the genotype-phenotype association is
not well understood because of the rarity of some of the
additional mutations. A recent systematic review demon-
strated that population-based CF carrier testing was asso-
ciated with a relatively high uptake, positive attitudes,
correct recall and understanding of carrier status, and no
long-term psychological harm [4]. Overall the implementa-
tion of carrier screening has also been shown to be associ-
ated with a modest reduction in the incidence of CF [4,5].
A time-related decrease in birth rate, with a mean annual
frequency of 0.16 (95% confidence interval, 0.09 to 0.23)
per 10,000 neonates, was reported by Castellani et al. [5].
The future: next-generation sequencing
In the past decade, the cost of DNA sequencing has been
greatly reduced due to the emergence of next-generation
sequencing (NGS) technologies. The major advance of-
fered by NGS is the ability to produce an enormous vol-
ume of DNA sequence inexpensively, allowing the rapid
and efficient testing of many genes and hundreds of muta-
tions concurrently. Furthermore, not only have NGS as-
says been shown to be extremely robust but they are also
reproducible and accurate [6]. NGS has facilitated the
accurate molecular diagnosis of clinically complex andgenetically heterogenous genetic disorders. NGS using
gene panels is currently being used for cancer, cardiomy-
opathy and autism screening.
Thus, pan-ethnic population carrier screening by NGS
for a large number of genetic disorders has now become
technically feasible. NGS carrier screens not only allow
the expansion of the number of mutations tested for,
and therefore the identification of rarer mutations, but
also make it possible to increase greatly the number of
genes screened for that are associated with a number of
different diseases. Utilizing NGS, Bell et al. [7] performed
carrier screening for 448 severe recessive disorders of
childhood. Although the technology has been shown to be
analytically accurate and reproducible, it presents a chal-
lenge that becomes more clinical in nature. The factors
that must be taken into account when performing massive
sequencing of healthy patients who wish to know their
carrier status and reproductive risk are different from
those that concern symptomatic patients who require a
molecular diagnosis by NGS. A major difference is that
the carrier testing should be accompanied by both pre-test
and post-test counseling to ensure that the individuals are
sufficiently informed of the implications of a positive or a
negative carrier test. Also, one issue that must be ad-
dressed prior to recommending pan-ethnic carrier screen-
ing is the development of educational materials as this
becomes a major challenge when testing for a large num-
ber of genes associated with a number of different dis-
eases. Prospective pilot studies should also be completed
in order to determine which genes should be included in
the panels, as well as patient preference and best practices
relating to patient counseling.
A screening program that is based on the DNA sequen-
cing of many genes will reveal not only pathogenic muta-
tions but also sequence variations of uncertain significance.
Whereas traditional carrier screening is designed to test
for the most common known mutations, NGS panels are
designed to test for all sequence changes. Such sequence
variations can pose difficulties for physicians and genetic
counselors when trying to convey accurate results to a po-
tential carrier. One of the mutations on the initial CF
panel was later found to be a polymorphism and was re-
moved from the original screening panel [8]. The carrier-
screening study by Bell et al. [7] found that 27% of the
mutations cited in the literature as being associated with
disease were polymorphisms or misannotated. Given the
large number of sequence variations that are likely to be
generated when screening a large number of genes, the
time and effort required to establish causality can be sig-
nificant. Also many of the true causative mutations identi-
fied will be very rare or novel with little known about
their clinical or prognostic impacts.
NGS carrier screening assays must be rigorously vali-
dated, both analytically and clinically, before entering
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a number of genes simultaneously by NGS is much less
than analyzing those genes individually, the additional
costs of interpretation of the results, reporting and gen-
etic counseling that result from NGS must be recognized
and dealt with. Most importantly, the data generated will
assist couples in making reproductive decisions relating
to a large number of severe recessive disorders. The num-
ber and choice of genetic tests available to patients will
continue to increase. There is no question that education
for both patients and physicians is a priority for a success-
ful carrier screening program; it is imperative that the re-
sults be conveyed to the patient in a comprehensive and
efficient manner.
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